BTK and Miyoshi myopathy: Because the majority of primary human MM cell samples express p-BTK protein and are sensitive to cytotoxic treatment with ibrutinib 10 μM in vitro [26], we selected INA-6 MM cells as a suitable model system to study the effects of ibrutinib in combination with proteasome inhibitors on MM cell lines in vitro.